Cargando…
Ocriplasmin use in a selected case with preserved visual acuity
BACKGROUND: Previous studies described cases of Ocriplasmin injections in patients with vitreo-macular traction and reduced central visual acuity. We describe the first case of a patient with 20/20 visual acuity and vitreo-macular traction treated with Ocriplasmin, and, for the first time in literat...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4625444/ https://www.ncbi.nlm.nih.gov/pubmed/26511080 http://dx.doi.org/10.1186/s12886-015-0141-9 |
_version_ | 1782397976017108992 |
---|---|
author | Rossi, Settimio Orrico, Ada Melillo, Paolo Testa, Francesco Simonelli, Francesca Della Corte, Michele |
author_facet | Rossi, Settimio Orrico, Ada Melillo, Paolo Testa, Francesco Simonelli, Francesca Della Corte, Michele |
author_sort | Rossi, Settimio |
collection | PubMed |
description | BACKGROUND: Previous studies described cases of Ocriplasmin injections in patients with vitreo-macular traction and reduced central visual acuity. We describe the first case of a patient with 20/20 visual acuity and vitreo-macular traction treated with Ocriplasmin, and, for the first time in literature, we evaluated the functional changes of the macula in response to pharmacological treatment through multifocal-electroretinogram. CASE PRESENTATION: We report the case of a female Caucasian patient aged 67 years with vitreo-macular traction in the right eye, treated with Ocriplasmin, at the Eye Clinic of the Second University of Naples. Visual acuity was 20/20 before treatment, associated with metamorphopsia. Two weeks after injection, optical coherence tomography showed the release of vitreo-macular traction and multifocal electroretinogram responses showed a significant increase of retinal density responses in all six rings (p < 0.03). Visual acuity remained constant with resolution of symptoms and the appearance of vitreous floaters. CONCLUSION: Intravitreal injection of Ocriplasmin resulted to be a safe and effective treatment in the case here reported. Our data show that the anatomical recovery with release of vitreo-macular traction was associated with a full functional recovery. In fact, the electrical retinal density response of the macular area improved two weeks after Ocriplasmin injection. Further studies with broader inclusion criteria for Ocriplasmin treatment (e.g. also with visual acuity higher than 20/25) on a larger study sample are needed to confirm our results. |
format | Online Article Text |
id | pubmed-4625444 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-46254442015-10-30 Ocriplasmin use in a selected case with preserved visual acuity Rossi, Settimio Orrico, Ada Melillo, Paolo Testa, Francesco Simonelli, Francesca Della Corte, Michele BMC Ophthalmol Case Report BACKGROUND: Previous studies described cases of Ocriplasmin injections in patients with vitreo-macular traction and reduced central visual acuity. We describe the first case of a patient with 20/20 visual acuity and vitreo-macular traction treated with Ocriplasmin, and, for the first time in literature, we evaluated the functional changes of the macula in response to pharmacological treatment through multifocal-electroretinogram. CASE PRESENTATION: We report the case of a female Caucasian patient aged 67 years with vitreo-macular traction in the right eye, treated with Ocriplasmin, at the Eye Clinic of the Second University of Naples. Visual acuity was 20/20 before treatment, associated with metamorphopsia. Two weeks after injection, optical coherence tomography showed the release of vitreo-macular traction and multifocal electroretinogram responses showed a significant increase of retinal density responses in all six rings (p < 0.03). Visual acuity remained constant with resolution of symptoms and the appearance of vitreous floaters. CONCLUSION: Intravitreal injection of Ocriplasmin resulted to be a safe and effective treatment in the case here reported. Our data show that the anatomical recovery with release of vitreo-macular traction was associated with a full functional recovery. In fact, the electrical retinal density response of the macular area improved two weeks after Ocriplasmin injection. Further studies with broader inclusion criteria for Ocriplasmin treatment (e.g. also with visual acuity higher than 20/25) on a larger study sample are needed to confirm our results. BioMed Central 2015-10-29 /pmc/articles/PMC4625444/ /pubmed/26511080 http://dx.doi.org/10.1186/s12886-015-0141-9 Text en © Rossi et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Case Report Rossi, Settimio Orrico, Ada Melillo, Paolo Testa, Francesco Simonelli, Francesca Della Corte, Michele Ocriplasmin use in a selected case with preserved visual acuity |
title | Ocriplasmin use in a selected case with preserved visual acuity |
title_full | Ocriplasmin use in a selected case with preserved visual acuity |
title_fullStr | Ocriplasmin use in a selected case with preserved visual acuity |
title_full_unstemmed | Ocriplasmin use in a selected case with preserved visual acuity |
title_short | Ocriplasmin use in a selected case with preserved visual acuity |
title_sort | ocriplasmin use in a selected case with preserved visual acuity |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4625444/ https://www.ncbi.nlm.nih.gov/pubmed/26511080 http://dx.doi.org/10.1186/s12886-015-0141-9 |
work_keys_str_mv | AT rossisettimio ocriplasminuseinaselectedcasewithpreservedvisualacuity AT orricoada ocriplasminuseinaselectedcasewithpreservedvisualacuity AT melillopaolo ocriplasminuseinaselectedcasewithpreservedvisualacuity AT testafrancesco ocriplasminuseinaselectedcasewithpreservedvisualacuity AT simonellifrancesca ocriplasminuseinaselectedcasewithpreservedvisualacuity AT dellacortemichele ocriplasminuseinaselectedcasewithpreservedvisualacuity |